In a report released yesterday, Rishi Jaluria from RBC Capital maintained a Hold rating on DocuSign (DOCU – Research Report), with a price ...
H.C. Wainwright raised the firm’s price target on Tourmaline Bio (TRML) to $50 from $49 and keeps a Buy rating on the shares following the Q4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback